30 reports of this reaction
1.6% of all ORPHENADRINE CITRATE reports
#10 most reported adverse reaction
DYSPNOEA is the #10 most commonly reported adverse reaction for ORPHENADRINE CITRATE, manufactured by Actavis Pharma, Inc.. There are 30 FDA adverse event reports linking ORPHENADRINE CITRATE to DYSPNOEA. This represents approximately 1.6% of all 1,883 adverse event reports for this drug.
Patients taking ORPHENADRINE CITRATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for ORPHENADRINE CITRATE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for ORPHENADRINE CITRATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 30 FDA reports for ORPHENADRINE CITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.6% of all adverse event reports for ORPHENADRINE CITRATE, making it a notable side effect.
If you experience dyspnoea while taking ORPHENADRINE CITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.